What is Zacks Research's Forecast for BHC FY2025 Earnings?

Bausch Health Companies Inc. (NYSE:BHC - Free Report) - Zacks Research cut their FY2025 EPS estimates for Bausch Health Companies in a research note issued to investors on Monday, January 20th. Zacks Research analyst R. Department now expects that the company will post earnings of $4.23 per share for the year, down from their previous forecast of $4.28. The consensus estimate for Bausch Health Companies' current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2026 earnings at $1.27 EPS and FY2026 earnings at $4.90 EPS.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.10. The firm had revenue of $2.51 billion for the quarter, compared to analysts' expectations of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. Bausch Health Companies's revenue was up 12.2% on a year-over-year basis. During the same quarter last year, the company posted $1.03 earnings per share.

Several other equities analysts have also commented on BHC. Royal Bank of Canada upped their price target on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a "sector perform" rating in a research report on Friday, November 1st. StockNews.com upgraded shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Friday, October 25th. Finally, Evercore ISI raised Bausch Health Companies to a "hold" rating in a report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $7.75.

Bausch Health Companies Trading Up 1.2 %

BHC traded up $0.10 during trading on Thursday, reaching $7.82. 1,568,070 shares of the company were exchanged, compared to its average volume of 3,642,190. The stock has a market cap of $2.83 billion, a P/E ratio of -16.28 and a beta of 0.69. Bausch Health Companies has a 52 week low of $3.96 and a 52 week high of $11.46. The firm has a 50 day moving average of $7.86 and a 200 day moving average of $7.45.

Institutional Trading of Bausch Health Companies

Institutional investors have recently made changes to their positions in the stock. DGS Capital Management LLC acquired a new position in shares of Bausch Health Companies during the fourth quarter valued at approximately $143,000. Merit Financial Group LLC acquired a new position in shares of Bausch Health Companies during the 4th quarter valued at $228,000. Sanders Morris Harris LLC raised its stake in shares of Bausch Health Companies by 16.0% in the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after buying an additional 4,000 shares in the last quarter. Northwest & Ethical Investments L.P. raised its stake in shares of Bausch Health Companies by 13.0% in the 3rd quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company's stock worth $264,000 after buying an additional 3,734 shares in the last quarter. Finally, Creative Planning boosted its stake in Bausch Health Companies by 16.9% during the third quarter. Creative Planning now owns 55,351 shares of the company's stock valued at $452,000 after buying an additional 7,995 shares in the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.